In summary, recent breakthroughs in HER2-targeted TKIs and ADCs are transforming outcomes in this rare NSCLC subset, though optimizing sequencing, managing resistance, and improving patient selection through biomarker development remain priorities for future research. Here, ERBB2 is linked to non-small cell lung carcinoma.